Beta Drugs Ltd vs Rubicon Research Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 06, 2026

Key Highlights

The Latest Trading Price of Beta Drugs Ltd is ₹ 1352 as of 06 May 15:30 . The P/E Ratio of Beta Drugs Ltd changed from 9.8 on March 2021 to 45.3 on March 2025 . This represents a CAGR of 35.82% over 5 yearsThe P/E Ratio of Rubicon Research Ltd changed from 0 on March 2021 to 0 on March 2025 . This represents a CAGR of 0.0% over 5 years The Market Cap of Beta Drugs Ltd changed from ₹ 115.37 crore on March 2021 to ₹ 1923 crore on March 2025 . This represents a CAGR of 75.55% over 5 yearsThe Market Cap of Rubicon Research Ltd changed from ₹ 0 crore on March 2021 to ₹ 0 crore on March 2025 . This represents a CAGR of 0.0% over 5 years The revenue of Beta Drugs Ltd for the Dec '25 is ₹ 89.58 crore as compare to the Sep '25 revenue of ₹ 106.37 crore. This represent the decline of -15.78% The revenue of Rubicon Research Ltd for the Dec '25 is ₹ 479.32 crore as compare to the Sep '25 revenue of ₹ 412.72 crore. This represent the growth of 16.14% The ebitda of Beta Drugs Ltd for the Dec '25 is ₹ 19.3 crore as compare to the Sep '25 ebitda of ₹ 24.3 crore. This represent the decline of -20.58% The ebitda of Rubicon Research Ltd for the Dec '25 is ₹ 111.91 crore as compare to the Sep '25 ebitda of ₹ 94.99 crore. This represent the growth of 17.81% The net profit of Beta Drugs Ltd changed from ₹ 8.95 crore to ₹ 8.52 crore over 5 quarters. This represents a CAGR of -3.86% The net profit of Rubicon Research Ltd changed from ₹ 25.57 crore to ₹ 72.8 crore over 7 quarters. This represents a CAGR of 81.83% The Dividend Payout of Beta Drugs Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 yearsThe Dividend Payout of Rubicon Research Ltd changed from -1.5 % on March 2023 to 0.18 % on March 2025 . This represents a CAGR of NaN% over 3 years .

About Beta Drugs Ltd

Beta Drugs Limited was incorporated as a private limited company with the name 'Beta Drugs Private limited' at Himachal Pradesh on September 21, 2005.
Subsequently, the company was converted in to public limited company and the name of the company was changed to 'Beta Drugs Limited' on August 11, 2017 Beta Drugs is a part of Adley Group.
Adley Group was founded in the year 1985, by its promoter Vijay Batra, who has more than twenty five years of experience in manufacture of pharmaceutical products in India.
The Company is a pharmaceutical formulation manufacturing company engaged in developing, manufacturing and marketing of drug products for domestic and international customers.
The Promoter Vijay Batra, took over the company from Kiran Goyal, Deepak Kumar Prince Bharti and Rohit Bansal in the year 2014.

About Rubicon Research Ltd

Rubicon Research Limited was incorporated on May 6, 1999, as a Private Company as Rubicon Consultants Private Limited', with the RoC. Subsequently, the Company's name was changed from Rubicon Consultants Private Limited' to Rubicon Research Private Limited' to which a fresh Certificate of Incorporation was issued by the RoC dated September 2, 2002.
The Company's status got converted from a Private Company to a Public Company, the name was changed from Rubicon Research Private Limited' to Rubicon Research Limited'.
A fresh Certificate of Incorporation dated July 23, 2024 was issued by the Central Processing Centre, Manesar, Haryana. Rubicon Research is an integrated pharmaceutical company with business encompassing the entire value chain in the research, development and production of pharmaceutical products.

FAQs for the comparison of Beta Drugs Ltd and Rubicon Research Ltd

Which company has a larger market capitalization, Beta Drugs Ltd or Rubicon Research Ltd?

Market cap of Beta Drugs Ltd is 1,338 Cr while Market cap of Rubicon Research Ltd is 15,841 Cr

What are the key factors driving the stock performance of Beta Drugs Ltd and Rubicon Research Ltd?

The stock performance of Beta Drugs Ltd and Rubicon Research Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Beta Drugs Ltd and Rubicon Research Ltd?

As of May 6, 2026, the Beta Drugs Ltd stock price is INR ₹1320.0. On the other hand, Rubicon Research Ltd stock price is INR ₹961.55.

How do dividend payouts of Beta Drugs Ltd and Rubicon Research Ltd compare?

To compare the dividend payouts of Beta Drugs Ltd and Rubicon Research Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.